Compare Global E Online Ltd (GLBE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Global E Online Ltd trades at $38.36 (market cap $6.55B), while Vertex Pharmaceuticals Incorporated trades at $485.29 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.5× Global E Online Ltd's market cap. Which is the better fit depends on your goals.
| GLBE | VRTX | |
|---|---|---|
Market Cap | $6.55B | $121.09B |
Sector | Technology | Health |
52-Week High | $41.59 | $529.59 |
52-Week Low | $27.54 | $366.54 |
Enterprise Value | $6.02B | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $38.43, down 0.84% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with 33% revenue growth and raised its full-year outlook. Recent acquisition of Passport aims to enhance logistics capabilities. Valuation ratios are elevated with a P/E of 58.18, reflecting high growth expectations.
Outlook remains positive driven by merchant expansion and cross-border e-commerce growth, but high valuation poses a risk if growth slows. Analyst consensus is unanimously bullish with a $38 price target, though recent insider sales and mixed quarterly EPS performance warrant monitoring.
Vertex Pharmaceuticals (VRTX) trades at $481.35, up 1.06% today, and is near its 52-week high. The stock shows a bullish technical signal with support at $471 and resistance at $482. Fundamentally, the company reported strong 2025 results with $12.0B revenue and $4.0B net income, though 2024 saw a loss. The recent $10B acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology pipeline, potentially adding $5B in peak sales.
Outlook remains positive with analyst consensus at 'Buy' and a $538 price target, implying 12% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. Earnings growth and pipeline expansion are primary catalysts, but investors should monitor execution on acquisitions and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
